FIELD: chemistry.
SUBSTANCE: present invention relates to new organoselenium compounds with formula IV. In formula IV: 
, A is 
; B is 
; R1 is independently C1-C4 alkyl; R2 is independently C1-C4 alkyl, substituted with at least one halogen, or is a halogen; R3 is hydrogen or 
R4 is hydrogen, alkali metal ion or C1-C7 alkyl; R5 is independently C1-C4 alkyl, substituted with at least one halogen, or is a halogen; m is an integer equal to 1, n is an integer ranging from 1 to 2; and p is an integer ranging from 0 to 3. The invention also relates to methods of producing formula IV compounds, method of obtaining an intermediate compound, pharmaceutical compositions which contain an organoselenium compound as an active component, as well as to intermediate compounds II, IIa and III.
EFFECT: obtaining compounds which have activity towards the receptor which is activated by peroxisomal proliferator δ(PPARδ) and can be used for treating cardiovascular diseases, reducing cholesterol level, diabetes or obesity.
10 cl, 3 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THIAZOLE DERIVATIVES AS PPAR-DELTA LIGANDS AND OBTAINMENT METHOD | 2006 |
|
RU2392274C2 |
| THIAZOLE DERIVATIVE AS PPARδ LIGAND AND PHARMACEUTICAL, COSMETICAL AND DIETARY FOOD CONTAINING IT | 2008 |
|
RU2444518C2 |
| DIARYL COMPOUNDS WITH BRIDGE BOND | 2002 |
|
RU2297409C2 |
| PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR APPLICATION | 2017 |
|
RU2746602C2 |
| SELENAZOLE DERIVATIVE, HAVING LIGAND ACTIVATING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR), METHOD FOR PRODUCTION THEREOF AND USE OF CHEMICAL COMPOUNDS | 2010 |
|
RU2510394C1 |
| VARIOLINE DERIVATIVES AND THEIR EMPLOYMENT AS ANTITUMOR AGENTS | 2002 |
|
RU2302419C2 |
| TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATING SKIN DISEASES | 2009 |
|
RU2544011C2 |
| AMINE DERIVATIVE POSSESSING NPY-Y5 RECEPTOR ANTAGONIST ACTIVITY, AND APPLICATION THEREOF | 2008 |
|
RU2460523C2 |
| SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | 2014 |
|
RU2667520C9 |
| SECONDARY MANNOSIS FOR BACTERIAL INFECTIONS TREATMENT | 2013 |
|
RU2667060C2 |
